Targeted protein degradation is currently being explored in its place technique in cancer, whereby the normal protein degradation process is co-opted for therapeutic uses. Recently designed novel molecules termed proteolysis-focusing on chimeras (PROTACs) are heterobifunctional molecules with two ligands joined by a linker. 1 ligand binds towards the ‘protein of https://www.directivepublications.org/journal-of-clinical-breast-cancer/